Morales Enrique, Gutierrez-Solis Elena, Gutierrez Eduardo, González Roberto, Martínez Miguel Angel, Praga Manuel
Servicio de Nefrología, Hospital 12 de Octubre, Avda, Andalucía s/n, 28041 Madrid, Spain.
Nephrol Dial Transplant. 2008 Dec;23(12):3901-7. doi: 10.1093/ndt/gfn407. Epub 2008 Jul 21.
Glomerular diseases other than HIVAN (HIV-associated nephropathy) are common among HIV patients but the information about their clinical characteristics and prognosis is very scarce. We have observed several HIV patients with glomerulonephritis in whom malignant hypertension (MHT) was the first clinical manifestation.
All HIV-infected individuals with a biopsy-proven glomerulonephritis at our hospital were reviewed. Information about clinical characteristics, histopathologic data and outcome was collected. The incidence of MHT among HIV and non-HIV patients with glomerulonephritis was studied.
Thirty HIV patients with glomerulonephritis were identified. Ten of them (33%) presented with MHT (severe hypertension and grade III hypertensive retinopathy). In comparison with patients without MHT, they showed a significantly higher blood pressure at presentation, a higher finding of IgA nephropathy (50% versus 15%; P < 0.05) and of malignant nephrosclerosis (60% versus 0%; P < 0.05) in renal biopsies, a higher viral load and a lower CD4+ cell count at the end of follow-up and a worse patient and renal survival: six patients (60%) started chronic dialysis and seven (70%) died after a follow-up of 11.8 +/- 16.2 and 39 +/- 35 months, respectively. Co-infection by HCV (hepatitis C virus) and HBV (hepatitis B virus) was very frequent among patients with malignant hypertension. The incidence of malignant hypertension among non-HIV patients with glomerulonephritis was significantly lower than that among HIV-infected patients.
Malignant hypertension is a common presentation of patients with HIV-associated glomerulonephritis, particularly in those with IgA nephropathy, and is associated with a very poor patient and renal survival.
除HIVAN(HIV相关性肾病)外的肾小球疾病在HIV患者中很常见,但关于其临床特征和预后的信息非常匮乏。我们观察到数例以恶性高血压(MHT)为首发临床表现的HIV相关性肾小球肾炎患者。
回顾了我院所有经活检证实为肾小球肾炎的HIV感染个体。收集了有关临床特征、组织病理学数据及转归的信息。研究了HIV感染和未感染的肾小球肾炎患者中MHT的发生率。
共确定了30例HIV相关性肾小球肾炎患者。其中10例(33%)表现为MHT(重度高血压和III级高血压性视网膜病变)。与无MHT的患者相比,他们在就诊时血压显著更高,肾活检中IgA肾病(50% 对15%;P < 0.05)和恶性肾硬化(60% 对0%;P < 0.05)的检出率更高,随访末期病毒载量更高、CD4+细胞计数更低,患者生存率和肾脏生存率更差:分别在随访11.8±16.2个月和39±35个月后,6例患者(60%)开始进行慢性透析,7例患者(70%)死亡。在恶性高血压患者中,丙型肝炎病毒(HCV)和乙型肝炎病毒(HBV)合并感染非常常见。非HIV感染的肾小球肾炎患者中恶性高血压的发生率显著低于HIV感染患者。
恶性高血压是HIV相关性肾小球肾炎患者的常见表现,尤其是在IgA肾病患者中,并且与患者生存率和肾脏生存率极低相关。